无需港股通，A股账户就能T+0买港股>> 恒生医疗保健指数涨超2%，恒生医疗ETF(513060)涨幅为2.09%，成交额2.93亿元，近1月份额减少 20.40%，减少56.83亿份，该基金支持T+0交易。 ...

金融界4月18日消息，A股三大指数收盘涨跌不一，中证全指医疗保健设备与服务指数 (医疗保健， H30178)下跌0.47%，报13068.08点，成交额93.53亿元。 数据统计显示，中证全指医疗保健设备与服务指数近一个月下跌8.95%，近三个月上涨0.01%，年至今 下跌4.09%。 据了解，中证全指医疗保健设备与服务指数从中证全指指数中选取与医疗保健主题相对应的行业内上市 公司证券作为指数样本，以反映该主题上市公司证券的整体表现。该指数以2004年12月31日为基日，以 1000.0点为基点。 从指数持仓来看，中证全指医疗保健设备与服务指数十大权重分别为：迈瑞医疗（9.41%）、爱尔眼科 （8.41%）、联影医疗（7.5%）、爱美客（3.79%）、惠泰医疗（3.54%）、鱼跃医疗（2.86%）、新产 业（2.82%）、美年健康（2.28%）、山东药玻（2.04%）、九安医疗（2.03%）。 从中证全指医疗保健设备与服务指数持仓的市场板块来看，深圳证券交易所占比60.21%、上海证券交 易所占比39.79%。 从中证全指医疗保健设备与服务指数持仓样本的行业来看，医药卫生占比100.00%。 资料显示，指数样 ...

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a mixed performance, with a recent increase but a decline over the past month and year-to-date [1] Group 1: Index Performance - The CSI Healthcare Equipment and Services Index rose by 0.32% to 13,285.51 points, with a trading volume of 13.924 billion yuan [1] - Over the past month, the index has decreased by 8.06%, while it has increased by 4.05% over the last three months and has declined by 3.25% year-to-date [1] Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, reflecting the overall performance of these securities [1] - The top ten weighted companies in the index include Mindray Medical (9.16%), Aier Eye Hospital (8.31%), and United Imaging Healthcare (7.43%) [1] - The index is primarily composed of companies listed on the Shenzhen Stock Exchange (60.27%) and the Shanghai Stock Exchange (39.73%) [1] Group 3: Sample Adjustment and Fund Tracking - The index samples are adjusted biannually, with adjustments occurring on the second Friday of June and December [2] - Public funds tracking the healthcare index include several funds from Southern Asset Management and Tianhong Asset Management [2]

HealthEquity (HQY) Q4 2025 Earnings Call March 18, 2025 04:30 PM ET Company Participants Richard Putnam - Investor RelationsScott Cutler - President, CEO & DirectorJames Lucania - CFO & Executive VPGlen Santangelo - Managing DirectorC. Gregory Peters - Managing Director - InsuranceAnne Samuel - Executive DirectorDavid Roman - Managing DirectorScott Schoenhaus - Managing DirectorStephen D. Neeleman - Founder & Vice ChairmanDavid Larsen - Managing DirectorSam Hasanov - Equity Research Associate Conference Cal ...

Financial Data and Key Metrics Changes - For Q4 2024, revenue totaled $39.2 million, a decline of 17.7% from Q4 2023, with case volume down 16.7% year-over-year [13][33] - Adjusted EBITDA was $1.9 million or 4.7% of revenue, compared to $10.1 million or 21.2% of revenue in the same quarter last year [16][38] - For the full year, revenues were $180.4 million, a decline of 7.9% from fiscal 2023, with adjusted EBITDA of $20.7 million and an adjusted EBITDA margin of 11.5% [18][39] Business Line Data and Key Metrics Changes - Same-store revenue declined 22.6% year-over-year in Q4 2024, reflecting challenges in the aesthetics market [13][33] - The average spend per procedure remained between $12,000 and $13,000, indicating a longer conversion time from leads to cases, increasing from approximately 45 days to closer to 60 days in the second half of 2024 [14][15] Market Data and Key Metrics Changes - The percentage of patients using financing for procedures was 50%, down from 53% in previous quarters, indicating a shift in consumer behavior [34] - The company operates in a $11 billion total addressable market in the U.S., highlighting significant growth potential despite current challenges [11] Company Strategy and Development Direction - The company aims to enhance its culture and align on a singular vision while improving its go-to-market strategy to drive consistent revenue growth [20][29] - Five key priorities include marketing to drive consumer interest, improving sales processes, introducing new services, enhancing customer experience, and leveraging technology [20][28] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging consumer backdrop affecting sales across the aesthetics space and emphasized the need for internal corrections [14][12] - The company expects Q1 2025 same-store sales performance to mirror Q4 2024 trends, with an anticipated sequential improvement as marketing spend increases [30][42] Other Important Information - The company has paused new center openings to focus on improving same-center performance and has amended its credit agreement to enhance investment flexibility [29][31] - Cash flow from operations for the year was $11.4 million, down from $24 million in fiscal 2023, with gross debt outstanding at $75.8 million [41] Q&A Session Summary Question: Can you provide more color on sequential growth expectations? - Management expects to see a similar seasonal trend with sequential improvement in same-store performance year-over-year, particularly in Q2 [51] Question: What are the liquidity improvement actions being taken? - The company drew down on its revolving credit facility to maintain marketing efforts while facing challenges in Q4 results [56] Question: How should we think about marketing spend versus customer acquisition cost (CAC)? - The elevated CAC was driven by lower case volumes and reduced lead volumes due to decreased marketing spend, but improvements in marketing strategy are expected to lower CAC in the future [62] Question: Can you elaborate on the cost savings program? - The company has executed a $3 million annual savings plan primarily through reductions in corporate headcount not aligned with the current strategy, with benefits expected to start in Q1 [67] Question: What specifics can you share about new marketing efforts? - The company is combining traditional paid search with new initiatives like online video and social marketing, focusing on a returns-based approach to optimize spending [72]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 Prenuvo已组建了 超大 规模 的专注于全身MRI检测的私人放射学团队 ，旗下拥有 80余位 获得专业认证 的放射科医师。凭借这一专业优势，公司与多家顶尖学术机构建立了研究合作关系，通过将MRI技术与人 工智能创新性结合，共同推进健康、衰老及疾病领域的科学研究。 Prenuvo拥有大型全身MRI影像数据库，有大量机会构建模型，以 提高其检查的准确性，并使其80位放 射科医生的工作更加高效。 报名：首届全球骨科大会 | 奖项评选 近日，医疗科技初创公司Prenuvo宣布已筹集了1.2亿美元（合约8.72亿人民币），本轮融资由 Forerunner Ventures、Left Lane Capital和现有投资者Felicis共同领投。 资金将用于为 其全身核磁共振扫描平台增加模式和分析功能，Prenuvo透露，其新的人工智能身体成分 报告软件已获得FDA批准。 # 融 资详情 Prenuvo公司宣布，该公司已通过其平台为会员群体提供了超过 140万条 个性化健康洞察，会员数量已 突破 11 ...